ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

PI3K p110beta/delta Inhibitor CVL237

Also written as “CVL237 tablets” and “KA2237”.

Its studies are mostly in Lymphoma, B-Cell, led by 2 companies.

Drug pagePI3K p110beta/delta Inhibitor CVL237: every studyAll 4 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Feb 18, 20244 company-led studies, 3 open or runningNext primary completion: Jan 9, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Convalife (Shanghai)its history only33 open or runningphase 3since Feb 18, 2024Nov 26, 2023Jan 9, 2028phase 2 · NCT07446049
Karus Therapeutics10 open or runningphase 1since Jan 29, 2016Jan 29, 2016none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Karus Therapeutics only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 29, 2016First study: phase 1 study in Lymphoma, B-CellFirst studyNCT02679196 · 23 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

The one study Karus Therapeutics leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02679196Lymphoma, B-Cell · United States1CompletedDec 24, 201823

How it is read

Names in the registry

  • “CVL237 tablets”, 3 entries
  • “KA2237”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.